Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS ANNOUNCES PRIVATE PLACEMENT OF UNITS FOR PROCEEDS OF UP TO $11 MILLION

Defence Therapeutics Inc. has launched a private placement of up to 20 million units at a price of 55 cents per unit, for aggregate gross proceeds to Defence of up to $11-million. Each unit will comprise one common share and one common share purchase warrant. Each warrant will entitle its holder to acquire an additional common share of the company at a price of 65 cents per share for 24 months following the date of issuance.

The company has executed a binding term sheet with two arm's-length institutional investors in connection with the private placement for aggregate gross proceeds of $6-million. In connection with the private placement, the investors' proceeds and the units will be deposited in escrow in advance of closing pursuant to an escrow agreement. Upon closing, the units will be released from escrow and delivered to the investors or as they may direct, and the investors' proceeds will be released from escrow and deposited as credit support pursuant to an ISDA credit support annex and released to the company in monthly cash tranches of $333,333 over an 18-month period, pursuant to the terms and conditions of a sharing agreement to be dated and executed on the closing of the private placement. Settlements under the sharing agreement shall commence five months after closing.

Pursuant to the sharing agreement, shares will be released in equal monthly instalments of approximately 606,060 shares over the 18-month term, with each release contingent upon the corresponding cash payment being delivered to the company. The sharing agreement shall provide that the company's economic interest will be determined in 18 monthly settlement tranches as measured against a benchmark price of 73.32 cents per share. If, at the time of settlement, the settlement price (determined monthly based on a 20-day volume-weighted average trading price of the company's shares on the Canadian Securities Exchange) exceeds the benchmark price, the company shall receive more than 100 per cent of the monthly settlement due, on a pro rata basis, with no upper limit on additional proceeds. If the settlement price is below the benchmark price, the company will receive less than 100 per cent of the monthly settlement due, on a pro rata basis. In no event will a decline in the settlement price result in an increase in the number of shares being issued to the investors. As a result, the company may ultimately receive more or materially less than the original proceeds of $6-million. The final amount received will depend on the company's future share price, which is subject to market fluctuations and may vary over time. Accordingly, there is no assurance as to the total amount the company will receive under the sharing agreement.

All 10,909,091 warrants to be issued shall be exercisable at an exercise price of 65 cents per share for a period of 24 months following the date of issuance. The warrants will include an equity blocker provision that prohibits the holder from exercising any portion of the warrants if such exercise would result in the holder owning more than 9.99 per cent of the company's outstanding shares.

The investors will receive a corporate finance fee of $360,000 in connection with the sharing agreement, payable in cash or via the issuance of 654,546 units at the private placement price, at the election of the company.

The company has agreed to pay a non-refundable deposit of $65,000 upon receipt of approval from the CSE in connection with the private placement. The deposit shall be satisfied by the issuance of 118,182 units at the private placement price.

Defence intends to use the proceeds from the private placement to advance its antibody drug conjugate (ADC) and radiopharmaceutical programs, to develop partnerships, and for working capital purposes. The company may pay finders' fees in connection with the offering to eligible arm's-length finders in accordance with the policies of the CSE.

Pursuant to applicable Canadian securities laws and in accordance with the exchange policies, all securities issued under this private placement will be subject to applicable resale restrictions under applicable securities laws. The closing of the private placement is expected on or about March 6, 2026, subject to the approval of the CSE.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursing cutting-edge science, and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most.

We seek Safe Harbor.